{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:21:48Z","timestamp":1760833308189,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2139,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Cretan Association for Biomedical Research (CABR"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.breast.2013.08.017","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T03:16:00Z","timestamp":1380597360000},"page":"1171-1177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A multicenter phase I\u2013II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"K.","family":"Tryfonidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Xenidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Christophyllakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Papakotoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Politaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.08.017_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.hoc.2007.03.001","article-title":"Chemotherapy for metastatic breast cancer","volume":"21","author":"Mayer","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.breast.2013.08.017_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/annonc\/mdp498","article-title":"Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer","volume":"21","author":"Mavroudis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.6004\/jnccn.2007.0025","article-title":"NCCN clinical practice guidelines, invasive breast cancer","volume":"5","author":"Carlson","year":"2007","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2013.08.017_bib5","first-page":"CD003372","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","volume":"2","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2013.08.017_bib6","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.1996.14.3.774","article-title":"Phase I-II study of 72 hour infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with metastatic breast cancer","volume":"14","author":"Fisherman","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"3 Suppl.\u00a06","key":"10.1016\/j.breast.2013.08.017_bib8","first-page":"105","article-title":"ECOG studies of paclitaxel and doxorubicin in advanced breast cancer","volume":"22","author":"Sledge","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib9","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1200\/JCO.1996.14.10.2713","article-title":"Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer","volume":"14","author":"Holmes","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0305-7372(93)90036-Q","article-title":"Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity","author":"Launchbury","year":"1993","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2013.08.017_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","article-title":"4-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data","volume":"10","author":"Ganzina","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2013.08.017_bib12","first-page":"337","article-title":"Phase II clinical evaluation of 4-Epidoxorubicin","volume":"67","author":"Hurteloup","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.breast.2013.08.017_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1023\/A:1026441804889","article-title":"Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study","volume":"10","author":"Kouroussis","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1023\/A:1008351310818","article-title":"Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study","volume":"11","author":"Mavroudis","year":"2000","journal-title":"Ann Oncol"},{"issue":"4 Suppl.\u00a013","key":"10.1016\/j.breast.2013.08.017_bib15","first-page":"11","article-title":"Docetaxel as single agent therapy in metastatic breast cancer: clinical efficacy","volume":"24","author":"Valero","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib16","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Docetaxel","volume":"13","author":"Cortes","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.breast.2013.08.017_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00001813-199608002-00003","article-title":"First-line treatment of metastatic breast cancer","volume":"7","author":"Trudeau","year":"1996","journal-title":"Anticancer Drugs"},{"issue":"4 Suppl.\u00a010","key":"10.1016\/j.breast.2013.08.017_bib18","first-page":"18","article-title":"Docetaxel (Taxotere) for the treatment of anthracycline resistant breast cancer","volume":"24","author":"Ravdin","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib19","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A\u00a0phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib20","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2013.08.017_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over","volume":"18","author":"Paridaens","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/sj.bjc.6602179","article-title":"Phase II multicentre randomized study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer","volume":"91","author":"Bonneterre","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.08.017_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/07357900600814060","article-title":"Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial","volume":"24","author":"Hainsworth","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.breast.2013.08.017_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00280-003-0690-0","article-title":"Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large multicentre phase II study","volume":"53","author":"Morales","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.breast.2013.08.017_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00280-006-0303-9","article-title":"TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity\/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC","volume":"59","author":"Malinovszky","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.breast.2013.08.017_bib26","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/annonc\/mdp115","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow up","volume":"20","author":"Cardoso","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib27","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2013.08.017_bib28","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placedo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2013.08.017_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.breast.2013.08.017_bib30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdq350","article-title":"Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial","volume":"22","author":"von Minckwitz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.08.017_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.2010.32.9060","article-title":"Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?","volume":"29","author":"Verma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2013.08.017_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.breast.2013.08.017_bib36","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1158\/1078-0432.CCR-05-1769","article-title":"Circulating tumor cells versus imaging \u2013 predicting overall survival in metastatic breast cancer","volume":"12","author":"Budd","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2013.08.017_bib37","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/annonc\/mdq052","article-title":"Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy","volume":"21","author":"Bidard","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2013.08.017_bib38","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/bcr2452","article-title":"Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients","volume":"11","author":"Kallergi","year":"2009","journal-title":"Breast Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:31:58Z","timestamp":1760776318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613002543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0960977613002543"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.08.017","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter phase I\u2013II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}